Paratek investor relations
WebApril 10, 2024. BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today ... Web7 Apr 2024 · See the latest Paratek Pharmaceuticals Inc stock price (NASDAQ:PRTK), related news, valuation, dividends and more to help you make your investing decisions.
Paratek investor relations
Did you know?
WebA disciplined team with proven capabilities in developing and commercializing new treatment options for complex medical issues. Meet Our Team Powered by You Our … WebBOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and …
Web16 Mar 2024 · Paratek routinely posts important information for investors on the Investor Relations section of its website at www.ParatekPharma.com. Paratek intends to use this website as a means of... Web27 Feb 2024 · Investor Relations EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders.
Web16 Mar 2024 · BOSTON, March 16, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate … Web25 Jul 2024 · The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 877-300-8521 and international investors should dial +1-412-317-6026. The conference ID is 10169245.
Web2 Aug 2024 · Clinical program successfully completed to support regulatory applications and potential approval in the U.S. and EUPre-NDA meetings with FDA conf...
Web3 Aug 2024 · Investor Relations: Hans Vitzthum LifeSci Advisors [email protected] Phone: 617-430-7578 Media: Christine Fanelle Scient PR [email protected] Phone: … 占い 大宮そごうWeb3 Jan 2024 · Paratek Pharmaceuticals' enterprise value of $369 million is less than 2X 2024 sales. ... Our analysts are third party authors that include both professional investors and individual investors who ... 占い 大宮Web16 May 2024 · Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or... 占い 大通Web1 Jul 2014 · /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today... Transcept Pharmaceuticals and... bcpx3 評価キット j80d1Web4 May 2024 · Paratek Pharmaceuticals Announces First Quarter 2024 Revenue of $24.9 Million Paratek Pharmaceuticals May 4, 2024, 4:05 PM · 10 min read Paratek Pharmaceuticals -- NUZYRA® (omadacycline)... bcp tsv インポートWeb3 Nov 2024 · Investor Relations: Hans Vitzthum LifeSci Advisors [email protected] Phone: 617-430-7578 Media: Christine Fanelle Scient PR [email protected] Phone: 215-595-5211 Paratek... bcp sqlserver オプション占い 大宮 安い